P. Tattersall, J. Kerr, S. Cotmore, M. Bloom, R. Linden et al., The evolution of parvoviral taxonomy, The parvoviruses, pp.5-14, 2006.

J. Cornelis, L. Deleu, U. Koch, J. Rommelaere, J. Kerr et al., Parvovirus oncosuppression, The parvoviruses, pp.365-84, 2006.
DOI : 10.1201/b13393-31

D. Piazza, M. Mader, C. Geletneky, K. Herrero-y-calle, M. Weber et al., Cytosolic Activation of Cathepsins Mediates Parvovirus H-1-Induced Killing of Cisplatin and TRAIL-Resistant Glioma Cells, Journal of Virology, vol.81, issue.8, pp.4186-98, 2007.
DOI : 10.1128/JVI.02601-06

S. Cotmore and P. Tattersall, Parvoviral Host Range and Cell Entry Mechanisms, Adv Virus Res, vol.70, pp.189-232, 2007.
DOI : 10.1016/S0065-3527(07)70005-2

J. Rommelaere, N. Giese, C. Cziepluch, and J. Cornelis, Parvoviruses as anti-cancer agents Viral therapy of human cancers, pp.627-75, 2005.

R. Randall and S. Goodbourn, Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures, Journal of General Virology, vol.89, issue.1, pp.1-47, 2008.
DOI : 10.1099/vir.0.83391-0

J. Nü-esch, J. Kerr, S. Cotmore, M. Bloom, R. Linden et al., Regulation of non-structural protein functions by differential synthesis, modification and trafficking, The parvoviruses, pp.275-89, 2006.

J. Nü-esch and J. Rommelaere, A viral adaptor protein modulating casein kinase II activity induces cytopathic effects in permissive cells, Proceedings of the National Academy of Sciences, vol.104, issue.30, pp.12482-12489, 2007.
DOI : 10.1073/pnas.0705533104

M. Moehler, M. Zeidler, V. Wilsberg, J. Cornelis, T. Woelfel et al., via Increased Phagocytosis, Maturation, and Cross-Presentation by Dendritic Cells, Human Gene Therapy, vol.16, issue.8, pp.996-1005, 2005.
DOI : 10.1089/hum.2005.16.996

S. Faisst, J. Schlehofer, and H. Zur-hausen, Transformation of human cells by oncogenic viruses supports permissiveness for parvovirus H-1 propagation, J Virol, vol.63, pp.2152-2160, 1989.

T. Dupressoir, J. Vanacker, J. Cornelis, N. Duponchel, and J. Rommelaere, Inhibition by parvovirus H-1 of the formation of tumors in nude mice and colonies in vitro by transformed human mammary epithelial cells, Cancer Res, vol.49, pp.3203-3211, 1989.

S. Faisst, D. Guittard, A. Benner, J. Cesbron, J. Schlehofer et al., Dose-dependent regression of HeLa cell-derived tumours in SCID mice after parvovirus H-1 infection, International Journal of Cancer, vol.66, issue.4, pp.584-593, 1998.
DOI : 10.1002/(SICI)1097-0215(19980209)75:4<584::AID-IJC15>3.0.CO;2-9

C. Van-pachterbeke, M. Tuynder, J. Cosyn, L. Lespagnard, D. Larsimont et al., Parvovirus H-1 inhibits growth of short-term tumor-derived but not normal mammary tissue cultures, International Journal of Cancer, vol.16, issue.4, pp.672-679, 1993.
DOI : 10.1002/ijc.2910550427

C. Van-pachterbeke, M. Tuynder, A. Brandenburger, G. Leclercq, M. Borras et al., Varying sensitivity of human mammary carcinoma cells to the toxic effect of parvovirus H-1, European Journal of Cancer, vol.33, issue.10, pp.1648-53, 1997.
DOI : 10.1016/S0959-8049(97)00153-6

K. Geletneky, M. Herrero-y-calle, J. Rommelaere, and J. Schlehofer, Oncolytic Potential of Rodent Parvoviruses for Cancer Therapy in Humans: A Brief Review, Journal of Veterinary Medicine Series B, vol.91, issue.7-8, pp.327-357, 2005.
DOI : 10.1093/jnci/93.12.903

M. Herrero-y-calle, J. Cornelis, C. Herold-mende, J. Rommelaere, J. Schlehofer et al., Parvovirus H-1 infection of human glioma cells leads to complete viral replication and efficient cell killing, International Journal of Cancer, vol.46, issue.1, pp.76-84, 2004.
DOI : 10.1002/ijc.11626

A. Angelova, M. Aprahamian, G. Balboni, H. Delecluse, R. Feederle et al., Oncolytic Rat Parvovirus H-1PV, a Candidate for the Treatment of Human Lymphoma: In Vitro and In Vivo Studies, Molecular Therapy, vol.17, issue.7, pp.1164-72, 2009.
DOI : 10.1038/mt.2009.78
URL : https://hal.archives-ouvertes.fr/pasteur-00748227

K. Geletneky, M. Herrero-y-calle, C. Herold-mende, C. Sommer, R. Koch et al., Complete remission of advanced autologous intracranial gliomas by oncolytic Parvovirus H1, Eur J Cancer, vol.3, p.53, 2005.

M. Hutt and D. Burkitt, ??TIOLOGY OF BURKITT'S LYMPHOMA, The Lancet, vol.301, issue.7800, p.439, 1973.
DOI : 10.1016/S0140-6736(73)90313-9

S. Chuang, W. Huang, P. Hsieh, Y. Jung, H. Ye et al., Sporadic paediatric and adult Burkitt lymphomas share similar phenotypic and genotypic features, Histopathology, vol.40, issue.4, pp.427-462, 2008.
DOI : 10.1016/j.blre.2006.02.001

H. Abali, Y. Urü-n, B. Oksü-zog-?lu, B. Budakog-?lu, N. Yildirim et al., Comparison of ICE (Ifosfamide-Carboplatin-Etoposide) Versus DHAP (Cytosine Arabinoside-Cisplatin-Dexamethasone) as Salvage Chemotherapy in Patients with Relapsed or Refractory Lymphoma, Cancer Investigation, vol.92, issue.4, pp.401-407, 2008.
DOI : 10.1056/NEJM199811193392104

H. Heslop, Biology and Treatment of Epstein-Barr Virus-Associated Non-Hodgkin Lymphomas, Hematology, vol.2005, issue.1, pp.260-266, 2005.
DOI : 10.1182/asheducation-2005.1.260

S. Wilop, O. Galm, R. Dada, R. Osieka, and E. Jost, Rituximab-associated changes in platelet count in patients with non-Hodgkin lymphoma, Leukemia & Lymphoma, vol.17, issue.8, pp.2116-2140, 2008.
DOI : 10.1096/fj.04-2126com

M. Ghetie, H. Bright, and E. Vitetta, Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin, Blood, vol.97, issue.5, pp.1392-1400, 2001.
DOI : 10.1182/blood.V97.5.1392

P. Farrell, G. Allan, F. Shanahan, K. Vousden, and T. Crook, p53 is frequently mutated in Burkitt's lymphoma cell lines, EMBO J, vol.10, pp.2879-87, 1991.

L. Flamand, I. Stefanescu, D. Ablashi, and J. Menezes, Activation of the Epstein-Barr virus replicative cycle by human herpesvirus 6, J Virol, vol.67, pp.6768-77, 1993.

R. Arcenas and R. Widen, Epstein-Barr virus reactivation after superinfection of the BJAB-B1 and P3HR-1 cell lines with cytomegalovirus, BMC Microbiology, vol.2, issue.1, p.20, 2002.
DOI : 10.1186/1471-2180-2-20

W. Hudson, Q. Li, C. Le, and J. Kersey, Xenotransplantation of human lymphoid malignancies is optimized in mice with multiple immunologic defects, Leukemia, vol.12, issue.12, pp.2029-2062, 1998.
DOI : 10.1038/sj.leu.2401236

E. Guetta, Y. Graziani, and J. Tal, Suppression of Ehrlich ascites tumors in mice by minute virus of mice, J Natl Cancer Inst, vol.76, pp.1177-80, 1986.

M. Mckisic, F. Paturzo, and A. Smith, MOUSE PARVOVIRUS INFECTION POTENTIATES REJECTION OF TUMOR ALLOGRAFTS AND MODULATES T CELL EFFECTOR FUNCTIONS1, Transplantation, vol.61, issue.2, pp.292-301, 1996.
DOI : 10.1097/00007890-199601270-00022

M. Mckisic, M. Jr, J. Delano, M. Jacoby, R. Paturzo et al., MOUSE PARVOVIRUS INFECTION POTENTIATES ALLOGENEIC SKIN GRAFT REJECTION AND INDUCES SYNGENEIC GRAFT REJECTION1, Transplantation, vol.65, issue.11, pp.1436-1482, 1998.
DOI : 10.1097/00007890-199806150-00005

N. Giese, Z. Raykov, L. Demartino, A. Vecchi, S. Sozzani et al., Suppression of metastatic hemangiosarcoma by a parvovirus MVMp vector transducing the IP-10 chemokine into immunocompetent mice, Cancer Gene Therapy, vol.9, issue.5, pp.432-474, 2002.
DOI : 10.1038/sj.cgt.7700457

Z. Raykov, G. Balboni, M. Aprahamian, and J. Rommelaere, Carrier cell-mediated delivery of oncolytic parvoviruses for targeting metastases, International Journal of Cancer, vol.5, issue.5, pp.742-751, 2004.
DOI : 10.1002/ijc.20013

Z. Raykov, S. Grekova, A. Galabov, G. Balboni, U. Koch et al., Combined oncolytic and vaccination activities of parvovirus H-1 in a metastatic tumor model, Oncology Reports, vol.17, pp.1493-1502, 2007.
DOI : 10.3892/or.17.6.1493

H. Toolan, E. Saunders, C. Southam, A. Moore, and A. Levin, H-1 Virus Viremia in the Human., Experimental Biology and Medicine, vol.119, issue.3, pp.711-716, 1965.
DOI : 10.3181/00379727-119-30278

S. Lang, N. Giese, J. Rommelaere, C. Dinsart, and J. Cornelis, Humoral immune responses against minute virus of mice vectors, The Journal of Gene Medicine, vol.119, issue.9, pp.1141-50, 2006.
DOI : 10.1002/jgm.940

M. Moehler, M. Zeidler, J. Schede, J. Rommelaere, P. Galle et al., Oncolytic parvovirus H1 induces release of heat-shock protein HSP72 in susceptible human tumor cells but may not affect primary immune cells, Cancer Gene Therapy, vol.10, issue.6, pp.477-80, 2003.
DOI : 10.1038/sj.cgt.7700591

M. Uhl, O. Kepp, H. Jusforgues-saklani, J. Vicencio, G. Kroemer et al., Autophagy within the antigen donor cell facilitates efficient antigen cross-priming of virus-specific CD8+ T cells, Cell Death and Differentiation, vol.157, issue.7, pp.991-1005, 2009.
DOI : 10.1172/JCI26321
URL : https://hal.archives-ouvertes.fr/pasteur-01402288

D. Green, T. Ferguson, L. Zitvogel, and G. Kroemer, Immunogenic and tolerogenic cell death, Nature Reviews Immunology, vol.283, issue.5, pp.353-63, 2009.
DOI : 10.1038/nri2545

A. Angelova, M. Aprahamian, S. Grekova, A. Hajri, B. Leuchs et al., Improvement of Gemcitabine-Based Therapy of Pancreatic Carcinoma by Means of Oncolytic Parvovirus H-1PV, Clinical Cancer Research, vol.15, issue.2, pp.511-520, 2009.
DOI : 10.1158/1078-0432.CCR-08-1088
URL : https://hal.archives-ouvertes.fr/pasteur-00748222

Z. Raykov, L. Savelyeva, G. Balboni, T. Giese, J. Rommelaere et al., B1 Lymphocytes and Myeloid Dendritic Cells in Lymphoid Organs Are Preferential Extratumoral Sites of Parvovirus Minute Virus of Mice Prototype Strain Expression, Journal of Virology, vol.79, issue.6, pp.3517-3541, 2005.
DOI : 10.1128/JVI.79.6.3517-3524.2005

Z. Raykov, S. Grekova, B. Leuchs, M. Aprahamian, and J. Rommelaere, Arming parvoviruses with CpG motifs to improve their oncosuppressive capacity, International Journal of Cancer, vol.10, issue.12, pp.2880-2884, 2008.
DOI : 10.1002/ijc.23472

F. Schmitz-winnenthal, L. Escobedo, P. Beckhove, V. Schirrmacher, M. Bucur et al., Specific immune recognition of pancreatic carcinoma by patient-derived CD4 and CD8 T cells and its improvement by interferongamma, Int J Oncol, vol.28, pp.1419-1447, 2006.

A. Battaglia, A. Buzzonetti, C. Baranello, G. Ferrandina, E. Martinelli et al., Metastatic tumour cells favour the generation of a tolerogenic milieu in tumour draining lymph node in patients with early cervical cancer, Cancer Immunology, Immunotherapy, vol.5, issue.Suppl 1, pp.1363-73, 2009.
DOI : 10.1007/s00262-008-0646-7

T. Wolter, R. Wong, S. Sarkar, and D. Zipris, DNA microarray analysis for the identification of innate immune pathways implicated in virus-induced autoimmune diabetes, Clinical Immunology, vol.132, issue.1, pp.103-118, 2009.
DOI : 10.1016/j.clim.2009.02.007

R. Prestwich, E. Ilett, F. Errington, R. Diaz, L. Steele et al., Immune-Mediated Antitumor Activity of Reovirus Is Required for Therapy and Is Independent of Direct Viral Oncolysis and Replication, Clinical Cancer Research, vol.15, issue.13, pp.4374-81, 2009.
DOI : 10.1158/1078-0432.CCR-09-0334

A. Krieg, Therapeutic potential of Toll-like receptor 9 activation, Nature Reviews Drug Discovery, vol.34, issue.6, pp.471-84, 2006.
DOI : 10.1038/nrd2059

L. Cesne, A. Dupressoir, T. Jamin, N. Spielmann, M. et al., Intra-lesional administration of a live virus, parvovirus H-1, in cancer patients: a feasibility study, Proc Am Soc Clin Oncol, vol.12, p.297, 1993.

R. Joerg, Schlehofer is a senior scientist in the Tumor Virology Division at the German Cancer Research Center (DKFZ) and apl-professor of Virology at the University of Heidelberg, Germany In his scientific career, he worked on picorna-and herpesviruses at the Free University of Berlin and at the University of Freiburg i.Br. where he then focused his interest on parvoviruses, notably adeno-associated viruses (AAV) Since 1984 he has been studying the biology and tumor-suppressive activity of AAV at the DKFZ, and also at the Pasteur Institute, the last few years he has joined the group of Jean Rommelaere in studies on the therapeutic use of oncolytic parvoviruses for human cancer. He has published more than 70 scientific papers and reviews in peer-reviewed journals and books, 1992.